A “triple whammy” in adenocarcinoma lung

A “triple whammy” in adenocarcinoma lung

Osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine-kinase inhibitor (TKI), is useful in the treatment of non-small cell lung cancer who show resistance to first-generation EGFR-TKIs and harbor T790M mutation. Acquisition of resistance to osimertinib due to sev...

Full description

Bibliographic Details
Main Authors: Mahismita Patro, Dipti Gothi, Sameer Vaidya, Ram Babu Sah
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Lung India
Subjects:
Non-small lung carcinoma
osimertinib resistance
triple mutation
Online Access:http://www.lungindia.com/article.asp?issn=0970-2113;year=2019;volume=36;issue=4;spage=340;epage=344;aulast=Patro

Internet

http://www.lungindia.com/article.asp?issn=0970-2113;year=2019;volume=36;issue=4;spage=340;epage=344;aulast=Patro

Similar Items